Fexapotide

Also called: Fexapotide triflutate; NX-1207; NX1207; NYM-4805

What it is

An investigational 17-amino-acid peptide (NX-1207) injected into the prostate for BPH and low-grade prostate cancer; long-term phase 3 data reported, not approved.

Approval status

In Clinical Trials. Not approved. openFDA's Drugs@FDA index returns no record for fexapotide (searched October 3, 2026). Two placebo-controlled phase 3 BPH trials (NCT00918983, NCT00945490, 500 each) and re-injection trials completed; a European phase 3 (NCT02003742) was terminated (ClinicalTrials.gov, read October 3, 2026).

Dosing, as printed in the page's Recommended Dosing box

Used in human trials

No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.

Protocol and source	Dose	Frequency	Duration	Route
Phase 3: benign prostatic hyperplasia (995 men, double-blind) **[Human study]** PMID 29380128	2.5 mg	Single injection, with open-label re-injection in crossover	Follow-up mean 3.58 years	Transrectal injection into the prostate
Grade Group 1 prostate cancer (146 men, randomised) **[Human study]** PMID 32088746	2.5 mg or 15 mg	Single injection	4-year follow-up	Transrectal injection into the prostate

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for "research use only" are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

Key human evidence

The 2 human studies carded on the page (9 study cards in all):

• **Long-term phase 3 BPH trials** (Human, 2018). In 995 men (3:2 fexapotide 2.5 mg:placebo; follow-up mean 3.58 years), long-term symptom improvement was greater (median -5.2 vs -3.0, $p < 0.0001$); acute urinary retention and prostate cancer incidence were lower; BPH intervention at 3 years was 8.08% vs 27.85% for oral medication crossover; no significant safety differences. **PMID 29380128**

• **Grade Group 1 prostate cancer** (Human, 2020). In 146 men randomised to 2.5 mg, 15 mg or active surveillance, a single injection significantly reduced progression to intervention over 4 years, with 15 mg superior to 2.5 mg and no drug-related serious adverse events. **PMID 32088746**

Interactions

A PubMed search for interaction studies of this compound with any drug (October 3, 2026, 0 records) found none in people. That is not evidence that it is safe to combine with anything.

Side effects and cautions

Reported side effects	Contraindications and cautions
• No significant safety differences from placebo in the long-term BPH trials • No drug-related serious adverse events in the prostate cancer trial	• Not approved for any use

Five questions to ask

1. Fexapotide is listed here as "In Clinical Trials". What does the evidence on this sheet mean for someone in my situation, and is there an approved treatment I should consider instead?
2. Here are the medicines and supplements I take. Do any of them interact with Fexapotide? This sheet records none published, which does not mean none exist.
3. Which side effects should make me stop and call you, for example no significant safety differences from placebo in the long-term bph trials?
4. Do any of the cautions on this sheet apply to me, such as: Not approved for any use?
5. What should we check before I start and while I am on it (blood tests, blood pressure, weight), and how often?

Grey Peptides is a vendor-neutral encyclopedia: it sells nothing and names no seller. This sheet is educational, not medical advice, and is not a prescription.